IMARA Inc. (IMRA) is increasing by 8% in premarket – Learn more!

IMARA Inc. (IMRA) experienced an increase of 8% in the premarket after the clearance of tovinontrine application by the FDA. However, the last trading session concluded at $1.5 with a decrease of 4.46%.

Clearance of tovinontrine application – What’s New?

On 25th January 2022, IMRA announced that FDA has approved the application for tovinontrine drug. Not only this but Imara expects to start a Phase 2 trial to investigate tovinontrine in patients 45 years and older with persistent HFpEF symptoms. The company is glad to contribute vast knowledge in clinical research and operations to patients suffering from HFpEF.

Moreover, the team expects to begin the Phase 2 study in the second quarter of 2022, with a design that focuses on identifying HFpEF patients with high PDE9 expression and implementing a focused strategy in this common ailment. Last but not the least, Tovinontrine is the best-in-class PDE9 inhibitor for research in this patient population, according to in vitro studies showing better potency and selectivity, and therefore less brain penetration than other PDE9 inhibitors.

Preclinical Data on IMR-261 – More updates

IMRA reported preclinical data on IMR-261 on 14th December 2021. Complexa, Inc. previously tested IMR-261, originally known as CXA-10, in Phase 2 clinical trials for FSGS and pulmonary arterial hypertension (PAH). Independent medical research suggests that it could be useful in a wide range of RBC illnesses, including hemoglobinopathies and iron excess.

These preclinical studies revealing the positive effect of IMR-261 in rodent models of sickle cell disease and beta-thalassemia have been very important. Induction of fetal hemoglobin is a successful technique for improving the pathophysiology of sickle cell disease, and my lab and other researchers have established the direct mechanistic role of Nrf2 in fetal hemoglobin reactivation. Lastly, the therapeutic potential of IMR-261 for the treatment of hemoglobinopathies is further highlighted by Nrf2-mediated protection against oxidative stress.

Leave a Comment

Your email address will not be published.